Literature DB >> 7694037

Serum betaine, N,N-dimethylglycine and N-methylglycine levels in patients with cobalamin and folate deficiency and related inborn errors of metabolism.

R H Allen1, S P Stabler, J Lindenbaum.   

Abstract

Homocysteine and 5-CH3-tetrahydrofolate (5-CH3-THF) are converted to methionine and THF by the CH3-cobalamin (CH3-Cbl)-dependent enzyme methionine synthase. Serum homocysteine levels are elevated in more than 95% of patients with Cbl or folate deficiency and in patients with inborn errors involving the synthesis of 5-CH3-THF or CH3-Cbl. Homocysteine and betaine are converted to methionine and N,N-dimethylglycine by betaine-homocysteine methyltransferase. It requires neither Cbl nor folate, although N,N-dimethylglycine is converted to N-methylglycine and then to glycine in reactions that both involve the formation of 5,10-CH2-THF from THF. Large amounts of betaine are often given orally to patients with inborn errors, even though little is known about its metabolism in normal subjects or these patients. Thus we developed new gas chromatographic-mass spectrometric assays for serum betaine, N,N-dimethylglycine, and N-methylglycine. In 60 blood donors, we found ranges for normal serum of 17.6 to 73.3, 1.42 to 5.27, and 0.60 to 2.67 mumol/L for the three metabolites, respectively, which were normal in the majority of 50 patients with Cbl deficiency, none of whom had increased levels of N-methylglycine. In 25 patients with folate deficiency, serum betaine level was normal in most, but 76% and 60% had elevations of N,N-dimethylglycine and N-methylglycine levels that ranged as high as 343 and 43.2 mumol/L, respectively. All of seven patients on betaine therapy for inborn errors had high values for betaine (167 to 3,900 mumol/L), N,N-dimethylglycine (15.1 to 250 mumol/L), and N-methylglycine (2.93 to 49.3 mumol/L). Serum total homocysteine levels remained very high at 47.2 to 156 mumol/L (normal, 5.4 to 16.2). In patients with cbl C and cbl D mutations, methionine levels remained low or low-normal at 8.3 to 15.6 mumol/L (normal, 13.3 to 42.7) despite betaine treatment. We conclude that (1) betaine levels are maintained in most patients with Cbl and folate deficiency; (2) levels of N,N-dimethylglycine and N-methylglycine are increased in most patients with folate deficiency; and (3) betaine therapy is relatively ineffective in patients with defective synthesis of CH3-Cbl.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7694037     DOI: 10.1016/0026-0495(93)90198-w

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  62 in total

1.  Sex-specific association of sequence variants in CBS and MTRR with risk for promoter hypermethylation in the lung epithelium of smokers.

Authors:  Kristina G Flores; Christine A Stidley; Amanda J Mackey; Maria A Picchi; Sally P Stabler; Jill M Siegfried; Tim Byers; Marianne Berwick; Steven A Belinsky; Shuguang Leng
Journal:  Carcinogenesis       Date:  2012-06-04       Impact factor: 4.944

2.  Two patients with hepatic mtDNA depletion syndromes and marked elevations of S-adenosylmethionine and methionine.

Authors:  S Harvey Mudd; Conrad Wagner; Zigmund Luka; Sally P Stabler; Robert H Allen; Richard Schroer; Timothy Wood; Jing Wang; Lee-Jun Wong
Journal:  Mol Genet Metab       Date:  2011-11-12       Impact factor: 4.797

3.  Metabolomics analysis revealed metabolic changes in patients with diarrhea-predominant irritable bowel syndrome and metabolic responses to a synbiotic yogurt intervention.

Authors:  Hamid Noorbakhsh; Masoud Yavarmanesh; Seyed Ali Mortazavi; Peyman Adibi; Ali A Moazzami
Journal:  Eur J Nutr       Date:  2018-11-03       Impact factor: 5.614

4.  S-Adenosylhomocysteine hydrolase deficiency: a second patient, the younger brother of the index patient, and outcomes during therapy.

Authors:  I Barić; M Cuk; K Fumić; O Vugrek; R H Allen; B Glenn; M Maradin; L Pazanin; I Pogribny; M Rados; V Sarnavka; A Schulze; S Stabler; C Wagner; S H Zeisel; S H Mudd
Journal:  J Inherit Metab Dis       Date:  2005       Impact factor: 4.982

5.  Constitutive induction of pro-inflammatory and chemotactic cytokines in cystathionine beta-synthase deficient homocystinuria.

Authors:  Amy K Keating; Cynthia Freehauf; Hua Jiang; Gary L Brodsky; Sally P Stabler; Robert H Allen; Douglas K Graham; Janet A Thomas; Johan L K Van Hove; Kenneth N Maclean
Journal:  Mol Genet Metab       Date:  2011-05-05       Impact factor: 4.797

6.  Betaine dose and treatment intervals in therapy for homocystinuria due to 5,10-methylenetetrahydrofolate reductase deficiency.

Authors:  N Sakura; H Ono; S Nomura; H Ueda; N Fujita
Journal:  J Inherit Metab Dis       Date:  1998-02       Impact factor: 4.982

7.  Enzyme Replacement Therapy Ameliorates Multiple Symptoms of Murine Homocystinuria.

Authors:  Tomas Majtan; Wendell Jones; Jakub Krijt; Insun Park; Warren D Kruger; Viktor Kožich; Steven Bassnett; Erez M Bublil; Jan P Kraus
Journal:  Mol Ther       Date:  2017-12-19       Impact factor: 11.454

8.  Maternal methionine adenosyltransferase I/III deficiency: reproductive outcomes in a woman with four pregnancies.

Authors:  S H Mudd; A Tangerman; S P Stabler; R H Allen; C Wagner; S H Zeisel; H L Levy
Journal:  J Inherit Metab Dis       Date:  2003       Impact factor: 4.982

9.  Pharmacokinetics of oral betaine in healthy subjects and patients with homocystinuria.

Authors:  Bernd C Schwahn; Dieter Hafner; Thomas Hohlfeld; Nina Balkenhol; Maurice D Laryea; Udo Wendel
Journal:  Br J Clin Pharmacol       Date:  2003-01       Impact factor: 4.335

10.  An indirect response model of homocysteine suppression by betaine: optimising the dosage regimen of betaine in homocystinuria.

Authors:  Angela Matthews; Trevor N Johnson; Amin Rostami-Hodjegan; Anupam Chakrapani; J Edward Wraith; Stuart J Moat; James R Bonham; Geoffrey T Tucker
Journal:  Br J Clin Pharmacol       Date:  2002-08       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.